comparemela.com

Sandoz News News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sandoz gets exclusive rights to commercialize biosimilar SB17 ustekinumab in US, Canada, EEA, Switzerland and UK

The reference medicine Stelara (ustekinumab) is a monoclonal antibody medication to interleukin (IL)-12/23 for the treatment of autoimmune disorders including Crohn s disease, plaque psoriasis,.

Sandoz concludes acquisition of antifungal agent Mycamine from Astellas

Basel: Sandoz has successfully completed the acquisition of worldwide brand rights for systemic antifungal agent Mycamine (micafungin sodium, Funguard in Japan) from Astellas.Through this acquisition.

Sandoz plans to build Biosimilar Technical Development Center in Slovenia

Basel: Sandoz has announced an investment of approximately USD 90 million at its site in Ljubljana, Slovenia to establish a dedicated Sandoz Biopharma Development Center by 2026.With this investment,.

Sandoz to move to new central Basel headquarters after spinoff

The move into the new office building will not impact the management of the Sandoz global business.

Novartis Sandoz division to go independent

The standalone Sandoz would be headquartered in Switzerland and listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.